3. Other secondary outcomes are the rate of early relapse rebound (assessed in all 200 patients prior to randomization), number of new GD+ lesions on MRI over the 12 months treatment period, defined as the period following the first infusion (month 0) to 6 months and 12 months after randomization, annualized relapse rate, and progression of neurological as assessed by changes in EDSS.